ABRAXANE® in Focus at International Conference
CANCER DRUG ABRAXANE® IN FOCUS AT INTERNATIONAL CONFERENCE Delegates to hear trial results for future possible ABRAXANE indications including ...
Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery
Melbourne, Australia May 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given ...
ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study
Melbourne, November 2012 Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study ...
Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation
Melbourne, June 2013 Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable ...
Updated Pancreatic Cancer Data Presented at International Cancer Conference
Melbourne, January 2014 – A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival ...
ICLUSIG™ to be PBS Listed November 1, 2015
ICLUSIG will be listed for the treatment of the following patients: Chronic Myeloid Leukaemia (CML) patients who are ...